ImageNet classification with deep convolutional neural networks
Alex Krizhevsky, Ilya Sutskever et al.
3.2k
Citations
0
Influential Citations
Nucleic Acids Research
Venue
2018
Year
Advancement in the field of computational research has made it possible for the in silico methods to offer significant benefits to both regulatory needs and requirements for risk assessments, and pharmaceutical industry to assess the safety profile of a chemical. Here, we present ProTox-II that incorporates molecular similarity, pharmacophores, fragment propensities and machine-learning models for the prediction of various toxicity endpoints; such as acute toxicity, hepatotoxicity, cytotoxicity, carcinogenicity, mutagenicity, immunotoxicity, adverse outcomes pathways (Tox21) and toxicity targets. The predictive models are built on data from both in vitro assays (e.g. Tox21 assays, Ames bacterial mutation assays, hepG2 cytotoxicity assays, Immunotoxicity assays) and in vivo cases (e.g. carcinogenicity, hepatotoxicity). The models have been validated on independent external sets and have shown strong performance. ProTox-II provides a freely available webserver for in silico toxicity prediction for toxicologists, regulatory agencies, computational and medicinal chemists, and all users without login at http://tox.charite.de/protox_II. The webserver takes a two-dimensional chemical structure as an input and reports the possible toxicity profile of the chemical for 33 models with confidence scores, and an overall toxicity radar chart along with three most similar compounds with known acute toxicity.
ProTox-II addresses a critical need in computational toxicology: the ability to rapidly and freely predict the toxicity of chemicals without relying solely on animal testing or expensive in vitro assays. By integrating multiple computational approaches—molecular similarity, pharmacophores, fragment propensities, and machine learning—the webserver offers a comprehensive toxicity profile for 33 endpoints, covering acute toxicity, organ-specific toxicity, and adverse outcome pathways. This is particularly important for regulatory agencies and the pharmaceutical industry, where early identification of toxic liabilities can save time and resources.
The paper's significance is underscored by its widespread adoption, with over 3,200 citations, indicating its impact on both academic research and industrial practice. ProTox-II democratizes access to toxicity prediction by providing a user-friendly, login-free webserver, enabling toxicologists, chemists, and regulators to perform in silico assessments. This aligns with the broader trend toward computational methods that reduce reliance on animal testing and accelerate the drug discovery process.
The abstract states that the models were validated on independent external sets and showed strong performance. However, specific metrics such as accuracy, sensitivity, or AUC are not provided in the abstract. The paper likely reports detailed performance metrics in the full text, but based on the abstract, the key result is the successful development and validation of the webserver. The high citation count suggests that the tool has been widely adopted and validated by the community.
ProTox-II represents a significant advancement in computational toxicology by providing a freely accessible, multi-endpoint toxicity prediction tool. Its impact extends beyond academia to regulatory agencies and the pharmaceutical industry, where it supports risk assessment and safety profiling. The integration of machine learning with traditional cheminformatics methods demonstrates the value of hybrid approaches in predictive toxicology. As the field moves toward more ethical and efficient testing strategies, tools like ProTox-II are likely to play an increasingly important role in reducing animal testing and accelerating the development of safer chemicals and drugs.
Alex Krizhevsky, Ilya Sutskever et al.
Ashish Vaswani, Noam Shazeer et al.
Douglas M. Bates, Martin Mächler et al.
Diederik P. Kingma, Jimmy Ba